Proactive Investors - Run By Investors For Investors

Regeneron Pharmaceuticals tops 3Q earnings and revenue estimates; shares edge higher

The drugmaker is trying to grow and diversity its business
medical test results
Regeneron is a biotechnology company whose main drug Eylea is used to treat blindness in the elderly

Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) third-quarter results topped both their earnings and revenue forecasts on stronger sales of their medical products, with shares getting a modest boost in premarket trading on Tuesday.

The company said earnings per share for the quarter reached $5.87 on net income of $675 million, exceeding the year-ago mark of $3.99 on net income of $470 million and the consensus of $5.13. Revenue clocked in at $1.66 billion, up 11% over last year's $1.5 billion and the street expectation of $1.64 billion.

"Regeneron continues to grow and diversify our business, while continuing to deliver very strong financial results.  In addition to EYLEA reaching over $1 billion in quarterly US net sales, we also made significant progress with Dupixent, a key driver of future growth, and launched Libtayo, our first immuno-oncology therapy," said Leonard Schleifer, the president and CEO of Regeneron.

Shares of Regeneron gained 0.3% to $356 in the premarket, having closed on Monday up 0.66% to $354.93.

READ: Regeneron higher after key drugs help deliver market-beating fourth quarter

In October 2018, the FDA approved Dupixent as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. EYLEA net product sales in the United States were $1.022 billion in the third quarter of 2018, compared to $953 million in the third quarter of 2017.

"Dupixent is now approved in the US for both atopic dermatitis and asthma and under regulatory review for the treatment of adolescents with atopic dermatitis - with another submission planned in chronic rhinosinusitis with nasal polyps. We also recently reported positive Phase 3 results for EYLEA in diabetic retinopathy and expect an FDA action on our supplemental application for this indication in the first half of 2019," Schleifer said.

Total revenues include Sanofi and Bayer collaboration revenues of $521 million in the third quarter of 2018, compared to $482 million in the third quarter of 2017.

Regeneron is a biotechnology company whose main drug Eylea is used to treat blindness in the elderly. 

The company is based in Eastview, New York.

Reporting by Rene Pastor, contactable on [email protected]

View full REGN profile View Profile

Regeneron Pharmaceuticals Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Social media use
Thu
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use